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Abstract
Objective. The preliminary classification criteria for SSc lack sensitivity for mild/early SSc patients, there-
fore, the new ACR/EULAR classification criteria for SSc were developed. The objective of this study was
to evaluate the performance of the new classification criteria for SSc in clinical practice in a cohort of mild/
early patients.
Methods. Consecutive patients with a clinical diagnosis of SSc, based on expert opinion, were prospect-
ively recruited and assessed according to the EULAR Scleroderma Trials and Research group (EUSTAR)
and very early diagnosis of SSc (VEDOSS) recommendations. In some patients, missing values were
retrieved retrospectively from the patient’s records. Patients were grouped into established SSc (fulfilling
the old ACR criteria) and mild/early SSc (not fulfilling the old ACR criteria). The new ACR/EULAR criteria
were applied to all patients.
Results. Of the 304 patients available for the final analysis, 162/304 (53.3%) had established SSc and
142/304 (46.7%) had mild/early SSc. All 162 established SSc patients fulfilled the new ACR/EULAR clas-
sification criteria. The remaining 142 patients had mild/early SSc. Eighty of these 142 patients (56.3%)
fulfilled the new ACR/EULAR classification criteria. Patients with mild/early SSc not fulfilling the new
classification criteria were most often suffering from RP, had SSc-characteristic autoantibodies and had
an SSc pattern on nailfold capillaroscopy. Taken together, the sensitivity of the new ACR/EULAR classi-
fication criteria for the overall cohort was 242/304 (79.6%) compared with 162/304 (53.3%) for the ACR
criteria.
Conclusion. In this cohort with a focus on mild/early SSc, the new ACR/EULAR classification criteria
showed higher sensitivity and classified more patients as definite SSc patients than the ACR criteria.
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Rheumatology key messages
. The new ACR/EULAR classification criteria for SSc are applicable in clinical practice.
. The new ACR/EULAR classification criteria have increased sensitivity compared with the previous ACR criteria.
. Some patients with features of early SSc are not covered by the new classification criteria.
Introduction
SSc is a heterogeneous disease that varies greatly between
individual patients, resulting in differences in organ involve-
ment, treatment and prognosis. There are particular chal-
lenges in recognizing mild and early forms of the disease.
Classification criteria for SSc are important for the uniformity
of disease cohorts, e.g. in clinical trials, but also for the early
detection of SSc to guide timely decisions on treatment
interventions. Several different classifications have been
proposed, most often based on the degree of skin involve-
ment [17]. The preliminary ACR classification criteria for
SSc were the first to be externally validated in a large popu-
lation of patients [8]. They have been applied successfully
for many years. However, the ACR criteria are limited by
their lack of sensitivity for mild and early cases of SSc.
This unmet need for greater sensitivity initiated revision
of the classification criteria by a joint effort of the EULAR
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and the ACR. Through a specific, predefined process of
item generation, item reduction and item validation, a final
set of clinical and laboratory features was chosen as the
new ACR/EULAR classification criteria [912]. These new
criteria now have to be applied and tested in clinical prac-
tice to show whether the limitations of the old criteria have
been successfully addressed. Therefore the aim of our
study was to evaluate the performance of the new ACR/
EULAR classification criteria for SSc in our real-life cohort
with a particular focus on mild and early SSc patients.
Methods
This was a single-centre observational study performed in
accordance with good clinical practice. All patients signed
informed consent according to the Declaration of Helsinki,
and the Cantonal Ethics Committee Zurich approved the
study. Consecutive patients with a clinical diagnosis of
SSc were prospectively recruited and assessed according
to EULAR Scleroderma Trials and Research group
(EUSTAR) and very early diagnosis of SSc (VEDOSS) rec-
ommendations [13, 14]. The clinical diagnosis of SSc was
based on the expert opinion of two experienced rheuma-
tologists (O.D. and B.M., 18 years and 5 years of experi-
ence in SSc assessment, respectively) from our tertiary
care university centre. Data from all patients were pro-
spectively collected in the database. Definitions of items
and data collection in this cohort are highly standardized.
More than 90% of patients are seen by the same two
physicians with long-term experience in SSc (B.M. and
O.D.). Data are collected directly during the visit on
paper and are afterwards transferred into the online
local database by a data entry clerk (N.S.). There is also
regular external independent monitoring for consistency
of key parameters with primary source data. As the new
ACR/EULAR criteria are cumulative, all available visits of
the patients were included in the analysis where appropri-
ate. Some items such as pitting scars and telangiectasia,
which were not collected prospectively, were retrieved
from the patient’s charts. Patients with missing data on
the classification items were excluded from the analysis
(n= 4).
The ACR criteria were used to classify patients into es-
tablished SSc (old ACR criteria fulfilled) or mild/early SSc
(old ACR criteria not fulfilled) [8]. Afterwards, the new
ACR/EULAR criteria were applied to these groups of es-
tablished and mild/early SSc [11, 12]. Scores for each
patient were calculated automatically using Excel soft-
ware (Microsoft, Redmond, WA, USA). Patients with a
total score 59 were classified as definite SSc patients
according to new ACR/EULAR classification criteria.
Distribution of the data was analysed by the d’Agostino
and Pearson omnibus normality test for continuous vari-
ables. Non-parametric data are shown as median and
interquartile range (IQR) if not indicated otherwise.
Frequencies are shown as percentage. Comparison of
sensitivity between ACR and ACR/EULAR criteria was
done by Fisher’s exact test.
Results
There were 308 patients with a clinical expert diagnosis of
SSc reported in the database. We excluded four patients
because of missing data on classification items that were
unavailable from patients’ charts. The final set of data for
analysis contained 304 patients. The final set was divided
into a group of 162 patients with established SSc who
fulfilled the ACR criteria and a group of 142 patients with
mild/early SSc who did not fulfil the ACR criteria. Baseline
characteristics and a comparison of these two groups of
patients are shown in Table 1. Demographics and clinical
characteristics were defined according to EUSTAR defin-
itions [15, 16].
We next applied the ACR/EULAR classification criteria
to both groups. All patients in the established group ful-
filled the new criteria. In the group of mild/early SSc pa-
tients, 80/142 (56.3%) fulfilled the new criteria, whereas
62/142 (43.7%) did not.
We further characterized the 80 patients who fulfilled
the new ACR/EULAR criteria, but not the old ACR criteria
(Table 2). Their median age was 58 years (range 4870),
disease duration was 6 years (range 316); 32/80 patients
(40%) had skin fibrosis with a median modified Rodnan
skin score (mRSS) of 0 (range 02) and a median score
with the new classification criteria of 10 (IQR 1014). Of
these 80 patients, 78 (97.5%) had RP, 71 (88.8%) had
SSc-related antibodies, 66 (82.5%) had abnormal nailfold
capillaries, 44 (55.0%) had puffy fingers and 34 (42.5%)
had telangiectasia (Table 2). In this group, 18/76 patients
(23.6%) had a disease duration of <3 years and 38/80
(47.5%) had gastrointestinal involvement.
We were also interested in characterizing the 62 pa-
tients with a clinical expert diagnosis of SSc who did not
fulfil the new ACR/EULAR classification criteria for SSc
(Table 2). Their median age was 54 years (range 3866),
disease duration was 6 years (range 212) and none of
them had skin fibrosis [median mRSS 0 (range 00)]. Of
these 62 patients, 58 (93.5%) had RP, 45 (72.6%) had
abnormal nailfold capillaroscopy findings, 37 (59.6%)
had SSc-related antibodies, 11 (17.7%) had puffy fingers
and 4 (6.4%) had telangiectasia. Pulmonary arterial hyper-
tension, interstitial lung disease, digital ulcers and pitting
scars occurred in only one patient (1.6%) (Table 2). Thus
the median score of those patients according to the
ACR/EULAR criteria was 7 (IQR 58). In this group,
22/54 patients (40.7%) had disease duration of <3 years
and 26/62 (41.9%) had gastrointestinal involvement.
Taken together, we found that in this cohort of
304 SSc patients with a focus on mild/early SSc, 162
(53.3%) fulfilled the previous criteria and 242 (79.6%) ful-
filled the new ACR/EULAR classification criteria for SSc.
Thus, in our cohort, the new ACR/EULAR classification
criteria showed significantly increased sensitivity
compared with the ACR criteria (P< 0.0001). Patients
with an expert diagnosis of SSc who did not fulfil the
new ACR/EULAR criteria most often had RP, an SSc pat-
tern on nailfold capillaroscopy, SSc-related antibodies
and puffy fingers.
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TABLE 1 Baseline characteristics of patients with established SSc and mild/early SSc
Established SSc Mild/early SSc P-value
Analysed patients, n/N (%) 162/304 (53.3) 142/304 (46.7)
Age, median (IQR), years 61 (5169) 56 (4368) 0.0003
dcSSc subset, n/N (%) 66/162 (40.7) 0/142 <0.0001
Sex, female, n/N (%) 132/162 (81.5) 126/142 (88.7) 0.1
mRSS, median (IQR) (minimummaximum) 8 (416) (037) 0 (00) (06) <0.0001
Disease duration, median (IQR), years 6 (313) 6 (213) 0.6
ANA status, n/N (%) 155/159 (97.5) 142/142 (100.0) 0.1
ACA, n/N (%) 51/159 (32.1) 89/142 (62.6) <0.0001
Anti-Scl-70, n/N (%) 51/161 (31.7) 13/139 (9.3) <0.0001
Anti-PM/Scl, n/N (%) 14/110 (12.7) 3/120 (2.5) 0.004
Anti-U1-snRNPa, n/N (%) 3/115 (2.6) 5/128 (3.9) 0.7
Anti-RNA polymerase III, n/N (%) 14/112 (12.5) 6/128 (4.6) 0.03
Digital ulcers, n/N (%) 67/162 (41.4) 6/142 (4.2) <0.0001
SSc pattern on nailfold capillaroscopy, n/N (%) 91/162 (56.2) 111/142 (78.1) <0.0001
RP, n/N (%) 153/159 (96.2) 136/142 (95.8) 1.0
Interstitial lung disease, n/N (%) 73/161 (45.3) 12/142 (8.4) <0.0001
PAH, n/N (%) 17/162 (10.5) 0/142 (0) <0.0001
Renal crisis, n/N (%) 4/162 (2.5) 1/142 (0.7) 0.4
GI involvement, n/N (%) 112/162 (69.1) 64/142 (45.1) <0.0001
Interstitial lung disease diagnosed by CT or, where not available, X-ray or forced vital capacity <70% without other explan-
ation; pulmonary arterial hypertension (PAH) diagnosed by right heart catheterization, which was performed when PAH was
suspected by expert opinion; renal crisis per the EUSTAR definition and confirmed by expert opinion; gastrointestinal (GI)
involvement diagnosed if there was involvement of the oesophagus, stomach or intestine, as per EUSTAR definition [15].
Demographics and clinical characteristics were defined according to EUSTAR definitions [16] and are provided in supple-
mentary Table S1 (available at Rheumatology Online). aAutoantibodies were measured and interpreted according to local
standards. GI: gastrointestinal; IQR: interquartile range (25th75th percentile); mRSS: modified Rodnan skin score; anti-Scl 70:
anti-topoisomerase 1 antibodies; anti-PM/Scl: antibodies against a nucleolar macromolecular complex of peptides of 75 kDa
and 100 kDa; anti-U1-snRNP: anti-U1 small nuclear ribonucleoprotein antibodies; PAH: pulmonary arterial hypertension.
TABLE 2 Characterization and comparison of mild/early patients who fulfilled and did not fulfil the new ACR/EULAR
classification criteria
Criteria Subcriteria
Patients who
fulfilled the
new ACR/EULAR
classification
criteria, n/N (%)
Patients who
did not fulfil the
new ACR/EULAR
classification criteria,
n/N (%) P-value
Skin thickening of the fingers
(count the higher of the two)
Puffy fingers 44/80 (55.0) 11/62 (17.7) <0.0001*
Whole finger, distal to MCP 30/80 (37.5) 0/62 <0.0001*
Fingertip lesions
(count the higher of the two)
Digital ulcers 5/80 (6.3) 1/62 (1.6) 0.2
Pitting scars 7/80 (8.7) 1/62 (1.6) 0.07
Telangiectasia 34/80 (42.5) 4/62 (6.4) <0.0001*
Abnormal NFC 66/80 (82.5) 45/62 (72.6) 0.02
Lung involvement PAH (on RHC) 3/80 (3.8) 1/62 (1.6) 0.6
ILD (on HRCT) 11/80 (13.8) 1/62 (1.6) 0.001*
RP 78/80 (97.5) 58/62 (93.5) 0.4
SSc-related antibodies Any of ACA, anti-Scl-70,a
anti-RNA polymerase III
71/80 (88.8) 37/62 (59.6) 0.0001*
aAutoantibodies were measured and interpreted according to local standards. HRCT: high-resolution CT; ILD: Interstitial
lung disease; NFC: nailfold capillaroscopy; PAH: pulmonary arterial hypertension; RHC: right heart catheterization; anti-Scl
70: anti-topoisomerase 1 antibody. *Statistically significant (P< 0.005).
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Discussion
The objective of this study was to evaluate the perform-
ance of the new ACR/EULAR classification criteria for SSc
in a cohort that reflects everyday clinical practice and has
a focus on mild and early SSc. This focus on mild patients
is an important difference from the cohorts that were
used to validate the classification criteria in the initial
approach [10].
We have chosen the term mild/early for this group, be-
cause this was a mixed group of patients with mild SSc
and longer disease duration (median 6 years) and a group
of early patients that did not (yet) fulfil ACR criteria [e.g.
13/54 patients (24.1%) had disease duration <2 years
from non-RP symptoms and 22/54 (40.7%) had disease
duration <3 years]. Thus mild/early SSc is a more correct
term than early SSc for this cohort. This is an important
result of our study and should be considered in the current
discussion of patients with early SSc [14, 17, 18]. In fact,
the current definition of patients with very early SSc might
be a heterogeneous group of patients with mild and early
SSc, which is probably paralleled by a different prognosis
and clinical course of the disease. Thus our data indicate
that cohorts of patients with early SSc should be analysed
separately from patients with mild SSc.
In a recent analysis, application of the new ACR/EULAR
classification criteria in southern Sweden resulted in a
3040% higher prevalence and incidence of SSc com-
pared with the 1980 ACR criteria [19]. We found that
53.3% of SSc patients fulfilled the previous criteria and
79.6% the new criteria and could thus show that
the new ACR/EULAR classification criteria allowed
classification of 26% more patients in our cohort
compared with the ACR criteria. These newly classified
patients were exclusively patients with mild and early dis-
ease, and accordingly, 56% of patients with mild/early
disease that could not be classified with the old criteria
met the new classification criteria. Therefore this study
confirms that the main aim of the new classification
criteria, i.e. increased sensitivity, was achieved.
Furthermore, our results showed that the new classifica-
tion criteria are applicable in clinical practice. Although we
confirmed that the new ACR/EULAR criteria have
increased sensitivity, one should be cautious about over-
diagnosing, because there are important psychological,
financial and other health consequences for patients diag-
nosed with early SSc, but who do not develop disease
over time.
However, it has to be emphasized that the new ACR/
EULAR criteria represent classification criteria and should
not be misinterpreted as diagnostic criteria. Along this
line, there were 62 patients (43.7% of the early/mild
cohort) in our cohort with a clinical expert diagnosis of
SSc who still did not fulfil the new criteria. These patients
were characterized most often by a combination of RP,
SSc-characteristic antibodies and an SSc pattern on nail-
fold capillaroscopy. These combinations of clinical fea-
tures resemble cases that were proposed to be named
early or limited SSc by LeRoy and Medsger [5]. Indeed,
patients with these clinical features can truly be named
SSc patients, as recent studies have shown that up to
65.9% of those patients develop definite SSc with add-
itional clinical manifestations at the 5 year follow-up [20].
Another more frequent clinical feature of this patient group
was puffy fingers, which has recently been proposed as a
pivotal sign for the suspicion of SSc in patients with very
early disease [14].
A limitation of our study was the inability to measure the
specificity of the new classification criteria in our cohort.
Since our registry does not contain SSc mimicker dis-
eases or patients with primary RP, we were unable to
measure the specificity of the test (the fraction of those
without disease correctly identified as negative by test).
Also, while most data were collected prospectively,
some data, such as pitting scars and telangiectasia,
had to be collected retrospectively. Furthermore, ex-
pert diagnosis is standard for this kind of study, and
both experts have long-standing experience, but expert
diagnosis might have been different with experts from
other centres.
Taken together, this study shows that the new ACR/
EULAR classification criteria for SSc are applicable in clin-
ical practice and have increased sensitivity compared with
the previous ACR classification criteria. This allows the
inclusion of patients with mild and early disease in SSc
cohorts and clinical studies. Our results also demonstrate
that despite their increased sensitivity, the new classifica-
tion criteria are not diagnostic criteria. In particular, pa-
tients with RP, SSc-characteristic antibodies and an SSc
pattern on nailfold capillaroscopy might still be diagnosed
with early SSc despite not fulfilling the new ACR/EULAR
classification criteria.
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